Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
neoplasm metastasis/diarrhea
Link salvestatakse lõikelauale
Leht 1 alates 54 tulemused
TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Background - Rationale Aflibercept The addition of aflibercept to the standard FOLFIRI regimen as second-line therapy was evaluated in a large phase III study (EFC10262-VELOUR). This combination significantly improved both PFS (4.7 to 6.9 months, HR=0.76; P=<0.001) and OS (12.1 to 13.5 months,
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
PRIMARY OBJECTIVES:
I. To evaluate and compare overall survival (OS) in patients with resectable pancreatic adenocarcinoma treated with perioperative fluorouracil, irinotecan hydrochloride, leucovorin calcium and oxaliplatin (modified [m]FOLFIRINOX) and surgery versus up-front surgery followed by
Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The main objective of the study is to assess whether the combination of ipatasertib and HP (+/- ET) is tolerable, especially in terms of the incidence and severity of diarrhea. For this purpose, up to a total of 25 patients will be enrolled in a staggered manner and evaluated.
A 3-cohort, descending
Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Lung cancer is the most common cancer, accounting for 20% of cancer-related deaths worldwide. In 2015, an estimated 610,200 patients (22 per cent of cancer-related deaths) died of lung cancer. Non-small cell lung cancer ((NSCLC)) accounts for 80% to 85% of lung cancer. Most patients are locally
Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING)
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Fecal Microbiota Transplantation in Diarrhea Induced by Tyrosine-kinase Inhibitors
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Despite the improvement in diagnosis and management, renal cell carcinoma (RCC) remains one of the most burdensome urological cancers, being the sixth most common malignancy in men and the 10th in women, accounting, respectively, for 5% and 3% of all cancers. Moreover, the incidence of RCC is
TheraSphere & Treatment of Unresectable Primary or Unresectable Secondary Liver Cancer
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Introduction
TheraSphere® TheraSphere® consists of insoluble glass microspheres where Y-90 is an integral constituent of the glass. The mean sphere diameter ranges from 20 to 30 µm. Each milligram contains between 22,000 and 73,000 microspheres. TheraSphere® is supplied in 0.6 mL of sterile,
Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy SCC of the Anal Canal (BISQUIT)
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Although anal canal squamous cell carcinoma (ACSCC) is rare in developed countries, it has shown an annual increase of 4% in its incidence in Brazil, and according to data from the Oncocenter Foundation of São Paulo (FOSP), 2,338 cases were diagnosed in 2000 and 2016.
The standard treatment for
Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Colorectal cancer (CRC) is a major cause of morbidity and mortality globally. More than 50% of patients can be expected to develop metastatic disease, and most of these patients will require palliative systemic therapy. The primary goal for patients who present with technically resectable liver
Exercises for Patients Who Were Receiving Chemotherapy
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Cancer-related mortality rates decreased considerably thanks to novel treatment methods and new agents over the last two decades. Although chemotherapy (CT) is an effective treatment type in reducing the size of the tumor and eliminating metastases, it may harm many different organs and systems due
Alectinib in Combination With Bevacizumab in ALK Positive NSCLC
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND The burden of Lung Cancer Lung cancer remains the most lethal malignancy worldwide, claiming more lives compared to any other malignant disease in both developed and developing countries, as well as globally. Although some countries have accomplished a decrease in incidence rates, most
Quality of Life and Psychological Vulnerability in Patients With RH+ Metastatic Breast Cancer
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Studying quality of life over time in patients followed for metastatic breast cancer will identify when a person may feel most vulnerable in their experience of the disease and treatment. A specific and adapted support can thus be set up throughout the disease, from the diagnosis and during the
Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Breast cancer is the most common non cutaneous cancer in U.S. women, with an estimated 63,960 cases of in situ disease and 266,120 cases of invasive disease in 2018. (American Cancer Society: Cancer Facts and Figures 2018). On the basis of ER, PR, and HER2/neu results, breast cancer is classified as
Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
This is an open-label, non-randomized, phase II clinical research study designed to assess the safety and efficacy of nivolumab and ipilimumab in combination with paclitaxel in patients with treatment naïve NSCLC.
Patients with histologically confirmed stage IV or recurrent non curable NSCLC of
Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
In 2015, 3500 patients were diagnosed with colon cancer in Denmark (DCCG Årsrapport 2015, www.dccg.dk). Despite curative intended surgery and perioperative chemotherapy in colon cancers, relapse is often encountered, and across tumor stage recurrence is found in 18-26% of the resected patients.
Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus
- Töötab 55 keeles
- Taimsed ravimid, mida toetab teadus
- Maitsetaimede äratundmine pildi järgi
- Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
- Lugege oma otsinguga seotud teaduspublikatsioone
- Otsige ravimtaimi nende mõju järgi
- Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega
Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel
